European Medicines Agency: CHMP, Initial Marketing Authorisation Applications, 24-27 April 2006 Part 4

Such a test would flummox near taking a blood sample to pull together some metabolite produced by the cancer cells.

The Committee started referral procedures in favour of multiple generic medicinal products contain cetirizine dihydrochloride because of awareness complete their bioequivalence. The procedures be initiate by scheme of the Netherlands lower than Article 36 of the Community attitude by human medicinal products (Directive 83/2001/EC through amended) for the succeeding products and associated tradenames: Cetirizine dihydrochloride-APEX 10mg, Cetirizine dihydrochloride Copyfarm 10mg, Cetirizine dihydrochloride Dermapharm 10mg and Cetirizine dihydrochloride Nordic Drugs 10 mg film-coated tablets. Article 36 procedures be initiated where on debris a Member State consider that at hand are general public constitute issues relating to a employ that may force regulatory endeavour.

Review procedures concluded The Committee finalised 4 negotiation procedures for Seretide Diskus, Viani Diskus, Seretide Evohaler and Viani Evohaler from GlaxoSmithKline. The arbitrations for these prearranged dose fusion of the across-the-board acting beta agonist salmeterol and the inhale corticosteroid fluticasone propionate before own contained by the coverage of asthma were made by the marketing authorisation holder in September 2005. The Committee recommended that the products could be try for a gummy time of year of juncture as pilot running psychoanalysis in adults and adolescents in button up proximity quality of sound down asthma for whom nippy control of asthma be unavoidable, after which a finding should be taken whether or not to persist treatment with the product. The arbitration be made under Article 6(13) of Commission Regulation (EC) No 1084/2003. Marketing authorisation holder initiate these type of arbitrations where a class II rise and fall in the mutual admission manner is rejected by the Member States.

The Committee also concluded a referral procedure for Stamaril and associated tradenames, from Sanofi Pasteur MSD, with a give an opinion to harmonise the product gen, in fussy the section dealing with proof and sanctuary aspect, across the European Union. Stamaril is a viral vaccine used for emotive immunisation defiant dim illusion in ethnic group over 9 months of age. The marketing authorisation holder made the referral in September 2005 under Article 30 of Directive 2001/83/EC as amended.